4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$15.01 USD
-0.24 (-1.57%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $15.02 +0.01 (0.07%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FDMT 15.01 -0.24(-1.57%)
Will FDMT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
Other News for FDMT
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
4D Molecular to host 4D-150 Wet AMD Development Day
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline